Fortress Biotech price target raised to $24 from $10 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Fortress Biotech to $24 from $10 and keeps a Buy rating on the shares. The analyst cites the mature advancement of several of the partner company assets to approval stage combined with assessed market opportunities for the target increase. The firm sees “significant upcoming regulatory milestones for Fortress’ partners.”